Lev Verkh

859 total citations
28 papers, 684 citations indexed

About

Lev Verkh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Lev Verkh has authored 28 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Lev Verkh's work include Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (11 papers) and Advanced Breast Cancer Therapies (7 papers). Lev Verkh is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (11 papers) and Advanced Breast Cancer Therapies (7 papers). Lev Verkh collaborates with scholars based in United States, Belgium and Italy. Lev Verkh's co-authors include John R. Crawford, Michael L. Levy, Steven C. Cramer, Nabil Dib, Laurie Sherman, Karen J. Klamerus, Jihao Zhou, John Smeraglia, Carlo L. Bello and Flemming Forsberg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lev Verkh

28 papers receiving 651 citations

Peers

Lev Verkh

ONCOL

PRM

GENET

HEMAT

Stéphanie Pesant United States

Vito Longo Italy

Irma M. Sáinz United States

Sarah L. Tressel United States

Aya Harada Japan

Johannes Fischer Germany

Bernard Lemieux Canada

Jeremy McGuire United States

Yinzhi Lai United States

Mélissa Taylor France

Stéphanie Pesant United States

Lev Verkh

503 ×2.2

241 ×1.2

ONCOL

167 ×0.9

PRM

165 ×1.1

GENET

336 ×3.5

HEMAT

Citations per year, relative to Lev Verkh Lev Verkh (= 1×) peers Stéphanie Pesant

Countries citing papers authored by Lev Verkh

Since Specialization

Citations

This map shows the geographic impact of Lev Verkh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lev Verkh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lev Verkh more than expected).

Fields of papers citing papers by Lev Verkh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lev Verkh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lev Verkh. The network helps show where Lev Verkh may publish in the future.

Co-authorship network of co-authors of Lev Verkh

This figure shows the co-authorship network connecting the top 25 collaborators of Lev Verkh. A scholar is included among the top collaborators of Lev Verkh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lev Verkh. Lev Verkh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kesari, Santosh, Gregory Kasper, Lev Verkh, et al.. (2021). Mesenchymal stem cells in the treatment of severe COVID-19. SHILAP Revista de lepidopterología. 6(1). 16–16. 1 indexed citations

Levy, Michael L., et al.. (2019). Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 50(10). 2835–2841. 143 indexed citations

Greene, Stephen J., Stephen E. Epstein, Raymond J. Kim, et al.. (2015). Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. Journal of Cardiovascular Medicine. 18(4). 283–290. 6 indexed citations

Bergh, Jonas, Gabriella Mariani, Fátima Cardoso, et al.. (2012). Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. The Breast. 21(4). 507–513. 21 indexed citations

Cardoso, Fátima, Jean‐Luc Canon, Dino Amadori, et al.. (2012). An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. The Breast. 21(6). 716–723. 12 indexed citations

Cardoso, Fátima, J-L. Canon, D. Amadori, et al.. (2009). Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer : Abstract #4120. Cancer Research. 69(2). 1 indexed citations

Robert, Francisco, Alan Sandler, Joan H. Schiller, et al.. (2009). Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology. 66(4). 669–680. 32 indexed citations

Kozloff, Mark, Ellen Chuang, Alex Starr, et al.. (2009). An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Annals of Oncology. 21(7). 1436–1441. 40 indexed citations

Cardoso, Fátima, J.-L. Canon, D. Amadori, et al.. (2009). 5075 Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer. European Journal of Cancer Supplements. 7(2). 283–283. 2 indexed citations

10.

Blay, Jean‐Yves, Aňa Lluch, Miguel Martín, et al.. (2009). Sunitinib (SU) in Combination with Trastuzumab (T) for the Treatment of Advanced Breast Cancer (ABC): Activity and Safety Results from a Phase II Study.. Cancer Research. 69(24_Supplement). 201–201. 3 indexed citations

11.

Cardoso, Fátima, J-L. Canon, D. Amadori, et al.. (2009). Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer.. Cancer Research. 69(2_Supplement). 4120–4120. 3 indexed citations

12.

Mariani, Gabriella, Fátima Cardoso, Tatiana Besse‐Hammer, et al.. (2008). Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation. Journal of Clinical Oncology. 26(15_suppl). 14534–14534. 9 indexed citations

13.

Kang, W., Narikazu Boku, Heewon Chung, et al.. (2007). 3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer. European Journal of Cancer Supplements. 5(4). 272–272. 3 indexed citations

14.

Bello, Carlo L., Laurie Sherman, Jihao Zhou, et al.. (2006). Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anti-Cancer Drugs. 17(3). 353–358. 114 indexed citations

15.

Spahn, Donat R., Klaus F. Waschke, Thomas Standl, et al.. (2002). Use of Perflubron Emulsion to Decrease Allogeneic Blood Transfusion in High-blood-loss Non-Cardiac Surgery. Anesthesiology. 97(6). 1338–1349. 100 indexed citations

16.

Hochberg, Fred H., Michael Prados, Christy Russell, et al.. (1997). Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study. Journal of Neuro-Oncology. 32(1). 45–55. 19 indexed citations

17.

Raza, Azra, Suzan Imren, Sefer Gezer, Lev Verkh, & James W. Freeman. (1989). Expression of nucleolar antigen p145 in bone marrow cells of patients with myeloid leukemias.. PubMed. 49(2). 482–7. 7 indexed citations

18.

Preisler, HD, Azra Raza, Richard A. Larson, et al.. (1989). Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study. Blood. 73(1). 255–262. 45 indexed citations

19.

Verkh, Lev, et al.. (1986). Changes in concentration of amino acids and other metabolites during hypothermie perfusion of the canine kidney. Cryobiology. 23(4). 366–370. 3 indexed citations

20.

Abbott, Robert, M. Anbar, Howard Faden, et al.. (1980). Diagnosis of viral infections by multicomponent mass spectrometric analysis.. Clinical Chemistry. 26(10). 1443–1449. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact